Industry by country
Biotechnology companies in United States
VCMC tracks 4,082 companies in Biotechnology based in United States. 842 of them have raised a venture or growth round, $65.76B in total, with a median round of $30M; 393 raised since 2024. 825 of the 842 have a VCMC valuation; the median is $129M.
4,082
companies tracked
842
venture-backed
21% of those tracked
$65.76B
raised in total
by 805 companies
$30M
median round
of 1,198 rounds with an amount
$129M
median valuation
of 825 companies valued
Values cover private companies only; public companies are not included.
By their latest round, most are at Series A (282 of 842).
- Pre-seed 17
- Seed 220
- Series A 282
- Series B 151
- Series C and later 166
- Stage not stated 6
The companies
Biotechnology companies in United States
The 50 venture-backed companies below are this page's list; Flagship Pioneering has raised the most ($3.60B).
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Flagship Pioneering Cambridge | Growth Equity Jul 2024 $3.60B | $45.6B | $16.1B – $69.4B | $29.0B (-36%) | $4.1B | 0% | 821 | up | C | |
| 2 | Retro Bio Redwood City | Series A Jan 2025 $1.00B | $10.0B | $5.4B – $11.5B | $10.0B (0%) | $1.4B | 0% | 99 | growing | B | |
| 3 | Xaira Therapeutics South San Francisco | Growth Equity Apr 2024 $1.00B | $15.2B | $4.9B – $23.1B | $9.1B (-40%) | $1.4B | 0% | 212 | up | C | |
| 4 | Element Biosciences San Diego | Series E Jun 2026 $175M | $2.4B | $1.4B – $4.4B | $2.9B (+18%) | $315M | 0% | 448 | flat | B | |
| 5 | Altos Labs Redwood City | Series B Jan 2022 $800M | $3.4B | $371M – $7.4B | $3.1B (-7%) | $928M | 23% | 549 | flat | D | |
| 6 | Inari Cambridge | Growth Equity Jan 2025 $144M | $1.4B | $738M – $2.5B | $1.0B (-26%) | $167M | 71% | 495 | down | C | |
| 7 | Enveda Boulder | Series E Sep 2026 $311M | $2.0B | $1.7B – $3.0B | $2.6B (+27%) | $286M | 0% | 381 | up | A | |
| 8 | Mirador San Diego | Series B Sep 2025 $250M | $2.8B | $1.2B – $4.3B | $2.8B (0%) | $307M | 0% | 97 | up | C | |
| 9 | NewLimit South San Francisco | Series C Jun 2026 $435M | $3.5B | $2.7B – $4.9B | $4.2B (+21%) | $464M | 0% | 64 | growing | A | |
| 10 | Arsenal Bio South San Francisco | Series C Sep 2024 $325M | $1.6B | $918M – $3.4B | $826M (-47%) | $368M | 97% | 168 | shrinking | C | |
| 11 | LifeMine Cambridge | Series E Aug 2026 $263M | $2.0B | $1.4B – $2.9B | $1.9B (-8%) | $288M | 97% | 32 | shrinking | B | |
| 12 | Ultima Genomics Fremont | Growth Equity Jun 2022 $600M | $3.8B | $419M – $10.1B | $3.7B (-3%) | $660M | 18% | 307 | flat | D | |
| 13 | Kriya Therapeutics Morrisville | Series D Sep 2025 $320M | $4.7B | $2.4B – $7.3B | $4.3B (-8%) | $566M | 28% | 194 | flat | B | |
| 14 | Tessera Therapeutics Somerville | Grant Oct 2025 $41M | $420M | $206M – $1.8B | $361M (-14%) | $437M | 97% | 210 | shrinking | D | |
| 15 | insitro South San Francisco | Series C Mar 2021 $400M | $1.1B | $195M – $5.8B | $1.0B (-10%) | $497M | 59% | 257 | flat | D | |
| 16 | Encoded Therapeutics South San Francisco | Series F Sep 2026 $275M | $3.6B | $2.3B – $6.8B | $4.5B (+26%) | $492M | 0% | 192 | up | B | |
| 17 | Kallyope New York | Series D Feb 2022 $236M | $236M | $93.0M – $1.8B | $223M (-6%) | $169M | 97% | 54 | down | D | |
| 18 | eGenesis Cambridge | Series D Sep 2024 $191M | $3.3B | $1.3B – $5.1B | $2.3B (-30%) | $368M | 0% | 154 | up | C | |
| 19 | Pathos Chicago | Series D May 2025 $365M | $2.1B | $1.3B – $2.5B | $2.1B (0%) | $235M | 0% | 98 | up | B | |
| 20 | Colossal Austin | Series C Jan 2025 $200M | $14.4B | $8.6B – $16.6B | $14.4B (0%) | $1.6B | 0% | 266 | up | B | |
| 21 | Brisbane | Series D Sep 2021 $195M | $457M | $95.8M – $1.8B | $402M (-12%) | $188M | 59% | 160 | down | D | |
| 22 | Lexington | Series B Dec 2025 $120M | $1.3B | $582M – $2.0B | $1.3B (+5%) | $146M | 0% | 65 | up | C | |
| 23 | Agoura Hills | Series C Aug 2024 $80M | $688M | $221M – $1.3B | $562M (-18%) | $100M | 44% | 117 | flat | C | |
| 24 | Series D Dec 2019 $125M | $164M | $88.2M – $427M | $164M (0%) | $179M | 97% | – | shrinking | C | ||
| 25 | Growth Equity Jan 2025 $200M | $2.4B | $1.4B – $3.7B | $2.4B (0%) | $220M | 0% | 53 | growing | B | ||
| 26 | Lexington | Series C Jan 2024 $75M | $543M | $138M – $1.2B | $306M (-44%) | $85.7M | 46% | 30 | flat | D | |
| 27 | Lexington | Series C Sep 2018 $80M | $101M | $54.3M – $292M | $101M (0%) | $122M | 97% | 53 | shrinking | C | |
| 28 | Seed May 2025 $155M | $2.1B | $574M – $3.1B | $2.1B (0%) | $372M | 0% | 44 | up | C | ||
| 29 | Brisbane | Series B Nov 2025 $65M | $715M | $344M – $1.0B | $731M (+2%) | $80.5M | 0% | 41 | flat | B | |
| 30 | Laguna Hills | Series B Aug 2026 $100M | $529M | $356M – $1.1B | $757M (+43%) | $83.3M | 0% | 42 | growing | B | |
| 31 | Sugar Land | Growth Equity Nov 2023 $40M | $458M | $128M – $752M | $410M (-10%) | $44.5M | 9% | 20 | up | C | |
| 32 | Series B Aug 2020 $123M | $162M | $40.0M – $1.1B | $159M (-2%) | $145M | 76% | 13 | down | D | ||
| 33 | Lexington | Series B Mar 2021 $110M | $345M | $24.3M – $427M | $323M (-6%) | $49.5M | 0% | 212 | flat | D | |
| 34 | Jericho | Series D Aug 2020 $71M | $323M | $38.5M – $845M | $323M (0%) | $92.4M | 30% | 65 | flat | D | |
| 35 | Natick | Series B Mar 2023 $50M | $255M | $42.5M – $761M | $201M (-21%) | $64.3M | 35% | 32 | flat | D | |
| 36 | Santa Cruz | Series B Mar 2026 $45M | $393M | $217M – $654M | $461M (+17%) | $50.7M | 0% | 70 | unknown | B | |
| 37 | Brisbane | Series A May 2025 $40M | $427M | $153M – $636M | $392M (-8%) | $69.8M | 23% | 39 | flat | C | |
| 38 | Southlake | Series B Jul 2023 $47M | $75.6M | $41.7M – $228M | $44.3M (-41%) | $45.9M | 97% | 29 | shrinking | C | |
| 39 | Concord | Series B Jan 2024 $75M | $888M | $261M – $1.4B | $606M (-32%) | $97.6M | 0% | 33 | up | C | |
| 40 | Hayward | Series A Mar 2022 $67M | $258M | $31.2M – $1.2B | $237M (-8%) | $145M | 48% | 29 | flat | D | |
| 41 | Monrovia | Series A Feb 2022 $60M | $572M | $40.5M – $1.1B | $544M (-5%) | $109M | 0% | 143 | up | D | |
| 42 | Series A Sep 2025 $58M | $636M | $236M – $968M | $636M (0%) | $89.1M | 0% | 64 | growing | C | ||
| 43 | Albany | Series A Feb 2021 $56M | $357M | $16.9M – $656M | $327M (-8%) | $78.4M | 0% | 101 | flat | D | |
| 44 | Brisbane | Series A Jan 2022 $55M | $106M | $20.7M – $685M | $101M (-5%) | $86.2M | 74% | 20 | down | D | |
| 45 | Davis | Series B Jul 2024 $30M | $215M | $68.3M – $406M | $140M (-35%) | $33.8M | 47% | 47 | down | C | |
| 46 | Thousand Oaks | Series A Apr 2021 $50M | $38.9M | $18.0M – $138M | $35.9M (-8%) | $70.0M | 97% | 36 | shrinking | D | |
| 47 | Natick | Series A Sep 2025 $50M | $531M | $192M – $808M | $531M (0%) | $74.3M | 0% | 21 | up | C | |
| 48 | Foster City | Series A Sep 2023 $48M | $307M | $39.9M – $698M | $269M (-13%) | $67.7M | 15% | 65 | flat | D | |
| 49 | Hayward | Series B Jul 2025 $31M | $243M | $128M – $370M | $203M (-17%) | $35.2M | 59% | 34 | flat | B | |
| 50 | Pear Bio Natick | Series A May 2023 $14M | $16.7M | $8.64M – $48.6M | $10.5M (-37%) | $16.1M | 97% | 9 | shrinking | C |
Showing 50 of 4,082. Load more lists every other company here, 50 at a time.
Valuations
How these companies are valued
825 of the 842 venture-backed companies here have a VCMC valuation; the median is $129M. A company acquired after its last round keeps its last value as a private company and is left out of the median. 30 companies have disclosed a valuation; for the rest VCMC's valuation is the only number. Each valuation comes with a range, from a low to a high scenario, and a prediction for a year from now. Values cover private companies only; public companies are not included. How VCMC values companies.
Investors
Who backs them
Firms that backed two or more of these companies. Alexandria Venture Investments backed 79, ARCH Venture Partners 54.
- Alexandria Venture Investments 79 companies, led 2
- ARCH Venture Partners 54 companies, led 17
- 44 companies, led 15
- 33 companies, led 8
- 30 companies, led 7
- Eli Lilly and Company 30 companies, led 2
- Y Combinator 29 companies, led 4
- GV 27 companies, led 4
- Invus 27 companies
- Khosla Ventures 24 companies, led 11
- 24 companies, led 3
- Cormorant Asset Management 23 companies, led 3
Recent rounds
Latest funding
152 rounds from Oct 2025 to Sep 2026, $7.97B with a disclosed amount.
- Series C, led by Ligand Pharmaceuticals $41M 24 Sep 2026
- Series C, with DFJ Growth and Premji Invest $75M 24 Sep 2026
- Enveda Series E, led by Catalio Capital Management $311M 23 Sep 2026
- Series A, led by LB Investment $10M 18 Sep 2026
- Series A, led by Leaps by Bayer amount not disclosed 17 Sep 2026
- Series A, with Schooner Capital and existing investors $30M 15 Sep 2026
- Encoded Therapeutics Series F, with GV and Undisclosed healthcare fund $275M 9 Sep 2026
- Series B, with Alpha Wave Global and YK Bioventures $70M 9 Sep 2026
- Series A, led by Insight Partners and Medical Excellence Capital $63M 9 Sep 2026
- Series A, led by Undisclosed private family fund and undisclosed private family fund and foundation $116M 8 Sep 2026
- Seed, led by 4BIO Capital $33M 8 Sep 2026
- Series B, led by BVF Partners, L.P. $60M 3 Sep 2026
Browse
Related groups
Wider groups
Biotechnology in other countries
Other industries in United States
Questions
Frequently asked
How many biotechnology companies in United States does VCMC track?
4,082. 842 of them have raised a venture or growth round.
How much have biotechnology companies in United States raised?
$65.76B in total across the 805 with a known amount; the median round is $30M. 393 raised a round since 2024.
Which biotechnology companies in United States have raised the most?
Flagship Pioneering ($3.60B), Retro Bio ($1.18B), Xaira Therapeutics ($1.00B).
Which investors back biotechnology companies in United States most often?
Alexandria Venture Investments (79 companies), ARCH Venture Partners (54 companies), RA Capital (44 companies).
What are biotechnology companies in United States worth?
The median VCMC valuation is $129M across 825 companies; companies acquired after their last round are left out. Values cover private companies only; public companies are not included.
What was the latest funding round?
AvenCell raised a Series C round of $41M (Sep 2026), led by Ligand Pharmaceuticals.